LabRoots and C&EN partnered to launch an exciting free virtual event – Precision Medicine 2016. A remarkable line-up of industry, government and academic experts, including architects of the Precision Medicine Initiative, showcased the latest advances in diagnostics, therapeutics and individualized medicine that are transforming the future of personalized healthcare.
Imagine receiving a full diagnosis from a simple blood test, or the ability to tailor the perfect treatment to your individual genetic makeup, taking into account your specific susceptibilities to side effects. What if we could apply a patient’s genetic information to gain insights into the genetic variations of diseases and expedite drug development, to create more precise therapies? This is the goal of Precision Medicine.
Precision Medicine is a new government initiative, calling for initial funding of $215 million to support the creation of a biobank of 1 million people and new efforts in cancer drug development. The initiative builds on stunning advances in next-generation sequencing, genome biology, cancer diagnostics, biomarkers, targeted drug development, adaptive clinical trials, and digital health.
Since the completion of the Human Genome Project, extraordinary progress has been made in understanding the reach and impacts of human genetic variation. Advances in sequencing, genomic analysis, biomarker detection, coupled with new insights into rational drug design and repurposing, have given doctors more powerful and selective tools to help treat disease by tailoring medicines to an individual's genetic profile.
This virtual conference allowed attendees to participate in a global setting with no travel or cost. Virtual events remove time and place restrictions and ensure that everyone who wants to participate can do so. This virtual conference also offered increased reach for the global research and medical communities with a high degree of interaction through live-streaming video and chat sessions.
- Next-Gen Sequencing in the clinic
- Therapies for Rare diseases
- Personalized cancer therapeutics
- Rational Drug Design
- Cancer diagnostics and liquid biopsies
- Alternative drug therapies
- Electronic Health Records
- Data Storage and Analytics